Prudentia Pulse™ Now Available! Click to Learn More -->
Contact UsSchedule Demo
MISSION
Prudentia’s AI-powered technology accelerates investment in breakthrough therapies that change the world.
I. Empowering biopharma to accelerate drug pipelines, maximize return on investment, and achieve clinical and commercial success for greater patient impact.
II. Enabling investors and biopharma to effectively position and showcase asset value during portfolio strategy planning and dealmaking.
III. Equipping investors with data-driven insights to optimize capital allocation in drug asset transactions.
Our Offerings
Real-time data driven simulation and scenario planning to optimize asset valuation for deal terms and enable speed to decision with increased deal throughput.
Rapid AI-powered synthesis of dataroom into an asset assessment framework enables comparison and contextualization with public and proprietary data and benchmarks to determine asset risks and value drivers.
AI-guided product profiles and asset valuations to guide portfolio strategy and decision making.
A concise and prioritized review of risks and opportunities for drug asset staging for emerging biotech and pharma.
Prudentia
Prism
Prudentia
Pinnacle
  Prudentia
  Panorama
Prudentia
Pulse
Prudentia
Pulse
A concise and prioritized review of risks and opportunities for drug asset staging for Biotechs.
Prudentia
Prism

Rapid AI-powered synthesis of data room into an asset assessment framework enables comparison and contextualization with public and proprietary data and benchmarks to determine asset risks and value drivers.
Prudentia Panorama
AI-Guided product profiles and asset valuations to guide portfolio strategy and decision making.
Prudentia
Delta
Real-time data driven simulation and scenario planning to optimize asset valuation for deal terms and enable speed to decision with increased deal throughput.
Traceable AI
  • Evidence-based insights
  • Transparent and explainable AI
Expert in the Loop
  • Human expertise is directly integrated with AI insights
Security
  • Customer-level data isolation
  • Advanced data encryption
  • Granular access control
Enterprise Scalable
  • Supports large teams and workflows
  • Fast, reliable performance at scale
The Challenge Facing Our Industry
Scientific due diligence is manual, multidisciplinary, complex, resource intensive and has persistent disconnect between scientific potential, clinical reality and financial valuation.
Why Prudentia Sciences
Prudentia Sciences is the operating system for life sciences deal-making.
Contact Us
What can companies do with Prudentia...
Expand capacity and resources to review more deals.
Improve collaboration with domain experts across R&D, clinical operations, and commercials across an organization.
Understand and maximize value drivers for assets.
Allocate capital efficiently by leveraging detailed insights.
Produce term sheets faster to analyze and close deals quickly.
Access industry experts and analytics at any time to evaluate the best investments.
DIFFERENTIATOR
“Our platform is designed to unlock the full potential of drug development and commercialization, ensuring that every dollar spent is optimized for impact.”
Throughput
Speed
Prudent Capital Allocation
Built for You
By leveraging human expertise with an AI-powered platform, Prudentia Sciences provides an adaptable system customized to your needs to support investment or allocation opportunities.
PHARMA
CEO & CFO
Allocate capital and optimize the value of your pipeline with internal assets and assets for licensing and M&A.
Research and Development
Deploy your team effectively to due diligence projects.
Business Development & Licensing
Accelerate the throughput of the deal pipeline and stage an asset for sale.
BIOTECH
Scientific Founders
Clarify asset value, risks, and readiness for investors.
Business Development Lead
Strengthen partner pitches with credible, data-driven valuations and asset staging.
Investors
VC & PE
Find the diamond in the rough through an accelerated process connecting diligence and valuation.
Hedge Funds
Quickly identify the alpha of mispriced assets in the marketplace.
Use Cases
Throughput: Screen the Market for the Next Big Opportunity
Learn More
Throughput: Screen the Market for the Next Big Opportunity
E.g. A Pharma is seeking to expand cardiometabolic portfolio. Head of BD&L aims to identify and qualify assets for acquisition or licensing that will grow R&D pipeline.
X
Speed: Informed Investment in an Asset
Learn More
Speed: Informed Investment in an Asset
E.g. A Pharma plans to invest/acquire approximately $750M in Phase II schizophrenia asset. Head of BD&L aim to do clinical and commercial diligence to achieve maximum Net Present Value (NPV).
Fast
Comprehensive
Decision-Support
X
Real-Time Simulation of Asset Value Scenarios
Learn More
Real-Time Simulation of Asset Value Scenarios
Our platform can address key questions in real-time.
Is it worth the cost and time to add a biomarker to increase the program pTRS?
Is it worth the cost to add trial sites to reduce cycle-time?
I must hit a budget target, how do I best preserve value in tradeoffs?
What is the variation in value given the variation in cost, time, and pTRS estimates?
Dynamic simulation to enable time, cost, pTRS, and revenue tradeoffs and what-if scenarios - tied to Prudentia’s Integrated Product Profile
X
Our Team
Sadiqa Mahmood
CEO & Founder
Ex - Health Catalyst, Broad Institute of Harvard & MIT, Mass General Brigham
John Reynders, PhD
Chief Technology Officer
Ex - Moderna, Alexion, J&J
Alek Walker
Senior Product Designer
& Marketing Specialist
Ex - Cordial, IQVIA
Alex Dreo
Senior Data Engineer
Ex - AIG, Persefoni
Benjamin Fleming
Senior Software Engineer
Ex - Amazon, Included Health
Duc Do, PhD
Senior Data Scientist
Ex - Beyond Limits, Persefoni
Sharon Tan
Scientific Lead
Ex - Ultragenyx, enGene, Enzyvent, Genzyme, Boston Scientific
Wasim Malik, PhD
Founding Board Member
Managing Partner, Iaso Ventures
Ex - Roivant Sciences, Mass General Hospital
Our Experts and Advisors
Matthew Leoni, MD, MBA 
Chief Medical Officer at Merida Biosciences
Ex - Cerevel, Otsuka, Novartis
Stuart Chaffee
CEO at QuantX Biosciences
Ex - Praxis Precision Medicines, Kymera Therapeutics, Affinivax
Travis May
CEO & Founder at Shaper Capital
Ex - Datavant, LiveRamp
News and Events
See All
Press Releases
Prudentia Sciences Launches Prudentia Pulse
Prudentia Sciences announces the release of Prudentia Pulse, its new product designed for nimble pharma and biotech teams navigating today’s high-stakes capital and partnering environment.
Read More
News
Exclusive: GV-backed startup Prudentia launches with $7M to help pharma make better deals, faster
Ahead of the busiest week for bio­phar­ma deal­mak­ing at the an­nu­al JP Mor­gan Health­care Con­fer­ence, a new start­up launched...
Read More
Press Releases
Prudentia Sciences Launches with $7M in Funding to Transform the Life Sciences Marketplace for Dealmaking
Prudentia Sciences, an AI-powered technology platform for life sciences announced today its public launch, supported by $7 million in funding.
Read More
Events
JPM Healthcare Conference 2025
Discover Prudentia Sciences at the 2025 JPM Healthcare Conference.
Read More
Investors and Partners
Book a Demo
Join Our Team
Let's Connect
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Let's Connect
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Close Cookie Popup
Cookie Settings
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device, including to enhance site navigation and analyze site usage. More info
Accept All Cookies
Cookie Settings
Close Cookie Preference Manager
Cookie Settings
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device, including to enhance site navigation and analyze site usage. More info